A. Schurr et al., PROTECTION BY MK-801 AGAINST HYPOXIA-INDUCED, EXCITOTOXIN-INDUCED, AND DEPOLARIZATION-INDUCED NEURONAL DAMAGE IN-VITRO, Neurochemistry international, 26(5), 1995, pp. 519-525
Exposure of rat hippocampal slices to 12-min hypoxia produced only mil
d neuronal damage, as 72% of all slices recovered their CA1-evoked pop
ulation spike following a 30-min recovery period. However, when this h
ypoxic insult was administered in the presence of 2.5 mu M kainate or
AMPA, only 6 and 15% of the slices, respectively, recovered their neur
onal function. This enhancement of hypoxic damage by kainate could be
attenuated in a dose-dependent fashion by the kainate/AMPA antagonist
GYKI 52466 but not by the competitive NMDA antagonist APV. Unexpectedl
y, the noncompetitive NMDA antagonist MK-801 also attenuated the kaina
te- and AMPA-enhanced hypoxic neuronal damage and was more efficacious
than GYKI 52466. Considering (1) the ability of MK-801 to antagonize
hypoxic neuronal damage in the absence or the presence of NMDA, kainat
e or AMPA; (2) the antihypoxic effect of MK-801 in the presence of APV
+ 7-chlorokynurenate, a pairing that supposedly blocks MK-801 binding
to the NMDA receptor; (3) the ability of MK-801 to protect hippocampa
l slices against brain damage induced by depolarization + excitotoxin
(50 mM KCl + mM glutamate for 60 min); and (4) the ability of diltiaze
m, an L-type calcium channel blocker, to protect hippocampal slices ag
ainst hypoxic neuronal damage, we conclude that the mode of action of
MK-801 cannot be explained by its NMDA receptor antagonistic propertie
s alone. A possible blockade of Ca2+ channels, most likely of the L-ty
pe, by MK-801 should be considered along with other mechanisms.